Century Therapeutics (IPSC) Return on Capital Employed (2021 - 2026)
Century Therapeutics' (IPSC) quarterly Return on Capital Employed came in at 44.01% in Q1 2026, down 3381.0% year-on-year from 1.34% in Q1 2025, and down 445.57% on a QoQ basis from 8.07% in Q4 2025.
Century Therapeutics (IPSC) Return on Capital Employed (2021 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has 6 years of Return on Capital Employed data on file, last reported at 44.01% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 3381.0% year-over-year to 44.01% in Q1 2026; TTM through Mar 2026 was 44.01%, a 3381.0% decrease from a year earlier, with the FY2025 full-year figure at 6.44%, up 5437.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 44.01%, down from 8.07% in the prior quarter.
- Over the last five years, Return on Capital Employed for IPSC reached as high as 8.07% in Q4 2025 and fell as low as 57.29% in Q4 2024.
- Historically, Return on Capital Employed has averaged 29.67% across 5 years, with a median of 28.96% in 2023.
- Across the five-year window, Return on Capital Employed soared 4922 bps in 2025 and plunged 3381 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 28.52% in 2022, then slumped by 42 bps to 40.56% in 2023, then sank by 41 bps to 57.29% in 2024, then surged by 86 bps to 8.07% in 2025, then slumped by 446 bps to 44.01% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 44.01% in Q1 2026, 8.07% in Q4 2025, and 13.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Century Therapeutics | 406.30 Mn | 271.49 Mn | - | -44.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.01% |
| Dec 31, 2025 | -8.07% |
| Sep 30, 2025 | -13.97% |
| Jun 30, 2025 | -11.42% |
| Mar 31, 2025 | -10.21% |
| Dec 31, 2024 | -57.29% |
| Sep 30, 2024 | -37.79% |
| Jun 30, 2024 | -40.03% |
| Mar 31, 2024 | -43.06% |
| Dec 31, 2023 | -40.56% |
| Sep 30, 2023 | -35.17% |
| Jun 30, 2023 | -31.66% |
| Mar 31, 2023 | -28.96% |
| Dec 31, 2022 | -28.52% |
| Sep 30, 2022 | -25.95% |
| Jun 30, 2022 | -23.58% |
| Mar 31, 2022 | -24.21% |
| Dec 31, 2021 | -21.67% |
| Sep 30, 2021 | -17.75% |